To evaluate the effect of diabetes medications on the risk of cardiovascular disease and surrogate markers.
Data Sources:
Literature was accessed through MEDLINE (1950–July 2008) and PubMed using multiple terms for diabetes, cardiovascular risk, surrogate markers, and diabetes medications. In addition, reference citations from publications were reviewed.
Study Selection and Data Extraction:
English-language articles that met the above criteria, with clinical relevance, were evaluated.
Data Synthesis:
Evidence regarding the effect of diabetes medications on cardiovascular risk is sparse, with information on their effects on surrogate markers more widely available. Recent evidence demonstrates that glycemic control alone may not reduce the risk of macrovascular events. Multiple trials were reviewed to determine the effect of diabetes medications on this risk, as well as the effect on surrogate markers (eg, blood pressure, cholesterol, body weight). Metformin and acarbose demonstrated significant reductions in macrovascular events, including myocardial infarction. Data regarding sulfonylureas, thiazolidinediones, and insulin are conflicting. Pioglitazone may reduce cardiovascular events, except heart failure, whereas rosiglitazone may increase these events. Until direct evidence can be obtained, the full effect of diabetes medications on cardiovascular risk is unknown.
Conclusions:
Current literature provides little support that diabetes medications may lower the risk of cardiovascular events while some agents may increase this risk. Of the drugs available, metformin may be the least detrimental. Current literature regarding other diabetes medications provides conflicting results on their effect on cardiovascular outcomes. In the meantime, practitioners should treat all targets of cardiovascular risk in patients with diabetes.
RosamondWFlegalKFurieK. Heart disease and stroke statistics 2008 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117;e25–e146; published online Dec 17, 2007; DOI 10.1161/CIRCULATIONAHA.107.187998.
2.
National Institute of Diabetes and Digestive Kidney Diseases. National diabetes statistics, 2007. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008. http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM_Statistics.pdf. (accessed 2008 Aug 27).
3.
NathanDMBuseJBDavidsonMB. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy—update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2008; 31: 173–5.
4.
RosenCJ. The rosiglitazone story—lessons from an FDA advisory committee meeting. N Engl J Med2007; 357: 844–6.
5.
BloomgardenZT. The Avandia debate. Diabetes Care2007; 30: 2401–8.
6.
StrattonIMAdlerAINeilAW. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ2000; 321: 405–12.
7.
HaffnerSMLehtoSRÿnnemaaTPyÿräläKLaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 339: 229–34.
8.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837–53.
9.
BuseJBGinsbergHNBakrisGL. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation2007; 115: 114–26.
10.
HeartWire. FDA advisory committee recommends cardiovascular safety studies for diabetes drugs. www.theheart.org/article/879839.do (accessed 2008 Jul 10).
11.
TurnerRCMillnsHNeilHAW. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ1998; 316: 823–8.
12.
TurnerRCHolmanRRStrattonIM., for the United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998; 352: 854–65.
13.
United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med1998; 128: 165–75.
14.
WulffeleMGKooyADe ZeeuwD. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med2004; 256: 1–14.
15.
GullifordMLatinovicR. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: Cohort study. Diabetes Metab Res Rev2004; 20: 239–45.
16.
JohnsonJASimpsonSHTothELMajumdarSR. Reduced cardiovascular morbidity and mortality associated with metformin in subjects with type 2 diabetes. Diabetic Med2005; 22: 497–502.
PogatsaGKoltaiMAJermendyG. The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients. Acta Med Hung1992; 49: 39–51.
19.
LeeTChouT. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab2003; 88: 531–7.
20.
BugosCAustinMAthertonTVierickC. Long term treatment of type 2 diabetes mellitus with glimepiride is weight-neutral: A meta-analysis (abstract P251). Diabetes Res Clin Pract2000; 50 (suppl 1): S47.
21.
BuseJBTanMHPrinceMJEricksonPP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab2004; 6: 133–56.
22.
University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II—mortality results. Diabetes1970; 19: 789–830.
23.
EvansJMMOgstonSAEmslie-SmithA. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia2006; 49: 930–6.
Product information. Avandia (rosiglitazone maleate). Research Triangle Park, NC: GlaxoSmithKline, November 2007.
26.
SarafidisPANilssonPM. The effects of thiazolidinediones on blood pressure levels—a systematic review. Blood Pressure2006; 15: 135–50.
27.
AnanFMasakiTFukunagaN. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest2007; 37: 709–14.
28.
ChiquetteERamirezGDeFronzoR. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med2004; 164: 2097–104.
29.
GoldbergRBKendallDMDeegMA. For the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care2005; 28: 1547–54.
30.
DeegMABuseJBGoldbergRB. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care2007; 30: 2458–64.
31.
DonnellyR. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. Int J Clin Pract2007; 61: 1160–9.
32.
ShimWSDoMYKimSK. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clinical Endocrinology2006; 65: 453–9.
33.
SparkmanJStroupJSchupachR. Metabolic effects of a conversion from rosiglitazone to pioglitazone in Native American patients with type 2 diabetes. Proc (Bayl Univ Med Cent)2007; 20: 349–53.
34.
SakamotoJKimuraHMoriyamaS. Activation of human peroxisome proliferator–activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun2000; 278: 704–11.
35.
MazzoneTMeyerPMFeinsteinSB. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA2006; 296: 257–81.
36.
NissenSENichollsSJWolskiK. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA2008; 299: 1561–73.
37.
DormandyJACharbonnelBEcklandDJA. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective piogliAzone Clinical Trial In macroVascular Events): A randomized controlled trial. Lancet2005; 366: 1279–89.
38.
ErdmannEDormandJACharbonnelBMassi-BenedettiMMoulesIKSkeneAM, on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol2007; 49: 1772–80.
39.
LincoffAMWolskiKNichollsSJ. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA2007; 298: 1180–8.
40.
KahnSEHaffnerSMHeiseMA. For the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med2006; 355: 2427–43.
41.
NissenSEWolskiK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007; 356: 2457–71.
42.
HomePDPocockSJBeck-NielsenH., for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med2007; 357: 28–38.
43.
SinghSLokeYKFurbergCD. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA2007; 298: 1189–95.
44.
MeneghiniLFFlorezHTamarizL. The Avandia debacle: Methodology and practical importance of the findings (letter). South Med J2007; 100: 1062–3.
45.
ShusterJJJonesLSSalmonDA. Fixed vs random effects meta-analysis in rare event studies: The rosiglitazone link with myocardial infarction and cardiac death. Statist Med2007; 26: 4375–85.
46.
LipscombeLLGomesTLévesqueLE. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA2007; 298: 2634–43.
47.
GerritsCMBhattacharyaMManthenaS. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf2007; 16: 1065–71.
48.
Product information. Precose (acarbose). West Haven, CT: Bayer Pharmaceuticals Corp., November 2004.
49.
HanefieldM. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol2007; 6: 20–9.
50.
The DECODE Study Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med2001; 161: 397–404.
51.
HanefieldMCagatayMPetrowitschT. Acarbose reduces the risk of myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J2004; 25: 10–6.
52.
HanefieldMChiassonJLKochlerC. Acarbose slows progression of initima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke2004; 35: 1073–8.
53.
ChiassonJLJosseRGGomisR. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM Trial. JAMA2003; 290: 486–94.
54.
RosenthalJHMauersbergerH. Effects on blood pressure of the α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest2002; 22: 695–701.
55.
ChiassonJLJosseRGGomisR. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet2002; 359: 2072–7.
56.
Van De LaarFALucassenPLBJ. No evidence for a reduction of myocardial infarctions by acarbose (letter). Eur Heart J2004; 25: 1179.
57.
Van De LaarFALucassenPLAkkermansRPVan De LisdonkEHRuttenGEVan WellC. α-Glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care2005; 28: 166–75.
58.
HolmanRRCullCATurnerRC, on behalf of the UKPDS Study Group. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care1999; 22: 960–4.
59.
Product information. Levemir (insulin detemir [rDNA origin]). Princeton, NJ: Novo Nordisk, Inc., October 2005.
60.
Yki-JärvinenH. Combination therapies with insulin in type 2 diabetes. Diabetes Care2001; 24: 758–67.
61.
HermansenKMoertensenLS. Bodyweight changes associated with antihyperglycemic agents in type 2 diabetes mellitus. Drug Safety2007; 30: 1127–42.
62.
KarterAJMoffetHHLiuJ. Glycemic response to newly initiated diabetes therapies. Am J Manag Care2007; 13: 598–606.
63.
MalmbergK, for the DIGAMI Study Group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction. I: Patients with diabetes mellitus. BMJ1997; 314: 1512–5.
64.
MalmbergKRydenLHamstenAHerlitzJWaldenstromAWedelH, on behalf of the DIGAMI study group. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J1996; 17: 1337–44.
65.
MalmbergKRydenLWedelH. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J2005; 26: 650–61.
66.
MelbinLGMalmbergKNorhammerAWedelHRydenL, for the DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: A report from the DIGAMI 2 trial. Eur Heart J2008; 29: 166–76.
67.
GersteinHCRosenstockJ. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: Can it offer both cardiovascular protection and beta-cell preservation?Endocrinol Metab Clin North Am2005; 34: 137–54.
68.
AbrairaCMcGuireDK. Intensive insulin therapy in patients with type 2 diabetes: Implications of the Veterans Affairs (VACSDM) feasibility trial. Am Heart J1999; 138: S360–5.
69.
OhkuboYKishikawaHArakiE. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non–insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diab Res Clin Pract1995; 28: 103–17.
70.
GenuthS. Exogenous insulin administration and cardiovascular risk in non–insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med1996; 124 (1 pt 2): 104–9.
71.
EurichDTMcAlisterFABlackburnDF. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. BMJ2007; 335: 497. DOI 10.1136/bmj.39314.620174.80.
72.
RajapolanRRosensonRSFernandesAWKhanMMurrayFT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: A retrospective data analysis. Clin Ther2004; 26: 1400–10.
AhrenB. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care2007; 30: 1344–50.
75.
Product information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., October 2007.
76.
InzucchiSEMcGuireDK. New drugs for the treatment of diabetes, part II: Incretin-based therapy and beyond. Circulation2008; 117: 574–84.
77.
BlondeLKleinEJHanJZhangB. Interim analysis of the effects of exenatide treatment on A1C, weight, and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab2006; 8: 436–47.
78.
Product information. Symlin (pramlintide). San Diego, CA: Amylin Pharmaceuticals, Inc., December 2007.
79.
WyshamCLushCZhangBMaierHWilhelmK. Effect of pramlintide as and adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin2008; 24: 79–85.
80.
VanDeKoppelSChoeHMSweetBV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm2008; 14: 363–80.
81.
ThompsonRGPearsonLSchoenfeldSLKoltermanOG, for the Pramlintide in Type 2 Diabetes Group. Pramlintide, a synthetic analog of human amalyin, improves the metabolic profiles of patients with type 2 diabetes using insulin. Diabetes Care1998; 21: 987–93.
82.
RiddleMFriasJZhangB. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care2007; 30: 2794–9.
83.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008; 358: 2545–59.
84.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008; 358: 2560–72.
GaedePVedelPLarsenN. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003; 348: 383–93.
87.
GaedePLund-AndersenHParvingHPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–91.
88.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ1998; 317: 713–20.
89.
AdlerAIStrattonIMNeilAW. Association of SBP with macrovascular and microvascular complications in type 2 diabetes (UKPDS 36): Prospective observational study. BMJ2000; 321: 412–9.
